{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:10:33Z","timestamp":1748664633293,"version":"3.41.0"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,19]],"date-time":"2015-09-19T00:00:00Z","timestamp":1442620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2015,9,19]],"date-time":"2015-09-19T00:00:00Z","timestamp":1442620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Rheum Dis"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1111\/1756-185x.12686","type":"journal-article","created":{"date-parts":[[2015,9,19]],"date-time":"2015-09-19T11:10:43Z","timestamp":1442661043000},"page":"231-237","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis"],"prefix":"10.1111","volume":"20","author":[{"given":"Arman","family":"Ahmadzadeh","sequence":"first","affiliation":[{"name":"Loghman Hospital; Shahid Beheshti University of Medical Sciences; Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza N.","family":"Farahmand","sequence":"additional","affiliation":[{"name":"Loghman Hospital; Shahid Beheshti University of Medical Sciences; Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latif","family":"Gachkar","sequence":"additional","affiliation":[{"name":"Loghman Hospital; Shahid Beheshti University of Medical Sciences; Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,19]]},"reference":[{"volume-title":"Biography of Tocilizumab for Rheumatoid Arthritis","year":"2009","author":"Emery","key":"10.1111\/1756-185X.12686-BIB0001|apl12686-cit-0001"},{"key":"10.1111\/1756-185X.12686-BIB0002|apl12686-cit-0002","first-page":"259","article-title":"Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody","volume":"20","author":"Wendling","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.12686-BIB0003|apl12686-cit-0003","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","article-title":"Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody","volume":"46","author":"Choy","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.12686-BIB0004|apl12686-cit-0004","first-page":"1426","article-title":"Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I\/II clinical study","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.12686-BIB0005|apl12686-cit-0005","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.12686-BIB0006|apl12686-cit-0006","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.12686-BIB0007|apl12686-cit-0007","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.12686-BIB0008|apl12686-cit-0008","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/1756-185X.12686-BIB0009|apl12686-cit-0009","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: results from a 24- week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.12686-BIB0010|apl12686-cit-0010","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.12686-BIB0011|apl12686-cit-0011","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.12686-BIB0012|apl12686-cit-0012","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","article-title":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.12686-BIB0013|apl12686-cit-0013","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0003-4967(24)43379-7","article-title":"Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages","volume":"60","author":"Boini","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.12686-BIB0014|apl12686-cit-0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1111\/1756-185X.12686-BIB0015|apl12686-cit-0015","first-page":"S29","article-title":"Patient questionnaires and formal education as more significant prognostic markers than radiographs or laboratory tests for rheumatoid arthritis mortality - limitations of a biomedical model to predict long-term outcomes","volume":"65","author":"Pincus","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1111\/1756-185X.12686-BIB0016|apl12686-cit-0016","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 1994 ICH harmonised tripartite guideline. clinical safety data management: definitions and standards for expedited reporting (E2a) http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf"},{"key":"10.1111\/1756-185X.12686-BIB0017|apl12686-cit-0017","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1111\/1756-185X.12686-BIB0018|apl12686-cit-0018","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/ard.2008.101964","article-title":"Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions","volume":"68","author":"Choy","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.12686-BIB0019|apl12686-cit-0019","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24\u00a0weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.12686-BIB0020|apl12686-cit-0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ard.2010.148700","article-title":"Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study","volume":"71","author":"Yazici","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.12686-BIB0021|apl12686-cit-0021","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-010-0366-7","article-title":"Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)","volume":"21","author":"Yamanaka","year":"2011","journal-title":"Mod Rheumatol"},{"issue":"Suppl 3","key":"10.1111\/1756-185X.12686-BIB0022|apl12686-cit-0022","first-page":"98","article-title":"Drug free REmission after cessation of Actemra Monotherapy (DREAM study)","volume":"69","author":"Imoto","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.12686-BIB0023|apl12686-cit-0023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/ijr.11.1","article-title":"Comparison of the Genant-modified Sharp and van der Heijde-modified Sharp scoring methods for radiographic assessment in rheumatoid arthritis","volume":"6","author":"Peterfy","year":"2011","journal-title":"Int J Clin Rheumtol"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12686","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/1756-185X.12686\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T18:32:12Z","timestamp":1748629932000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,19]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12686","archive":["Portico"],"relation":{},"ISSN":["1756-1841"],"issn-type":[{"type":"print","value":"1756-1841"}],"subject":[],"published":{"date-parts":[[2015,9,19]]}}}